Meeting News
Advertisement
Non-Hispanic Black women had the highest odds for hypertensive disorders of pregnancy, preterm birth, and fetal death.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
CR1-02 was well-tolerated and led to stable disease in patients with relapsed or refractory AML.
Advertisement
Gaurav Goyal, MD, spoke to Blood Cancers Today about strategies and guidelines for incorporating PROs into clinical trials.
Tycel Phillips, MD, discussed his presentation on BTK inhibitors from the International Ultmann Chicago Lymphoma Symposium.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
CML clinical expert Nikolai Podoltsev, MD, PhD, especially addresses the capabilities of tyrosine kinase inhibitors.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.